Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

• Status: Completed
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nalagenetics Pte Ltd
• Treatments: Tamoxifen

Criteria

Inclusion Criteria:

• Diagnosed with ER+ breast cancer

• Have taken tamoxifen daily for at least 2 months

Exclusion Criteria:

• Have not taken tamoxifen daily for at least 2 months